A Prospective Randomized Trial of Intravitreal Bevacizumab or Laser Therapy in the Management of Diabetic Macular Edema (BOLT Study)
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Stearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 6,090
(1985) · Archives of Ophthalmology · doi:10.1001/archopht.1985.01050120030015 · Cited by 2,540
Turner, R. D., & Holman, R. R. (1998) · Cited by 1,974
Epidemiology of Diabetes and Diabetes-Related Complications
Deshpande, A. D., Harris-Hayes, M., & Schootman, M. (2008) · Physical Therapy · doi:10.2522/ptj.20080020 · Cited by 1,773 · cited 3×
“(B) Exclusion criteria (ocular criteria were applied to the study eye only): (1) macular ischemia (foveal avascular zone [FAZ] 1000 m greatest linear dimension (GLD) or severe perifoveal intercapillary loss on FFA); (2) macular edema due to a cause other than DME; (3) coexistent ocular disease: (i) a preexisting ocula…”
BackgroundMethodInfluentialDiabetic Macular Edema: Pathogenesis and Treatment
Bhagat, N., Grigorian, R. A., Tutela, A., & Zarbin, M. A. (2009) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2008.10.001 · Cited by 571
(2008) · Ophthalmology · doi:10.1016/j.ophtha.2008.06.015 · Cited by 548
INTRAVITREAL BEVACIZUMAB (AVASTIN) THERAPY FOR PERSISTENT DIFFUSE DIABETIC MACULAR EDEMA
HARITOGLOU, C., KOOK, D., NEUBAUER, A., WOLF, A., PRIGLINGER, S., STRAUSS, R., GANDORFER, A., ULBIG, M., & KAMPIK, A. (2006) · Retina · doi:10.1097/01.iae.0000247165.38655.bf · Cited by 453
Klein, R., Knudtson, M. D., Lee, K. E., Gangnon, R., & Klein, B. E. K. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2008.10.016 · Cited by 415
(2009) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2008.610 · Cited by 398
Nguyen, Q. D., Shah, S. M., Heier, J. S., Do, D. V., Lim, J., Boyer, D., Abraham, P., & Campochiaro, P. A. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2009.04.023 · Cited by 340
Chun, D. W., Heier, J. S., Topping, T. M., Duker, J. S., & Bankert, J. M. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2006.04.033 · Cited by 295
Effect of Ruboxistaurin on Visual Loss in Patients with Diabetic Retinopathy
(2006) · Ophthalmology · doi:10.1016/j.ophtha.2006.07.032 · Cited by 276
(2007) · Archives of Ophthalmology · doi:10.1001/archopht.125.4.469 · Cited by 274
Soheilian, M., Ramezani, A., Obudi, A., Bijanzadeh, B., Salehipour, M., Yaseri, M., Ahmadieh, H., Dehghan, M. H., Azarmina, M., Moradian, S., et al. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2009.01.011 · Cited by 220
KOOK, D., WOLF, A., KREUTZER, T., NEUBAUER, A., STRAUSS, R., ULBIG, M., KAMPIK, A., & HARITOGLOU, C. (2008) · Retina · doi:10.1097/iae.0b013e318176de48 · Cited by 164
ELECTROPHYSIOLOGIC FINDINGS AFTER INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENT
Maturi, R. K., Bleau, L., & Wilson, D. L. (2006) · Retina · doi:10.1097/00006982-200603000-00003 · Cited by 157
(2007) · Archives of Ophthalmology · doi:10.1001/archopht.125.3.318 · Cited by 153
Causes of blind certifications in England and Wales: April 1999–March 2000
Bunce, C., & Wormald, R. (2007) · Eye · doi:10.1038/sj.eye.6702767 · Cited by 147
Self-citationSoheilian, M., Ramezani, A., Bijanzadeh, B., Yaseri, M., Ahmadieh, H., Dehghan, M. H., Azarmina, M., Moradian, S., Homa, T., & Peyman, G. A. (2007) · Retina · doi:10.1097/iae.0b013e31815ec261 · Cited by 140
Primary Intravitreal Bevacizumab for Diffuse Diabetic Macular Edema
Arévalo, J. F., Sánchez, J. G., Wu, L., Maia, M., Alezzandrini, A., Brito, M., Bonafonte, S., Lujan, S., Díaz-Llopis, M., Restrepo, N. A., et al. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2009.03.016 · Cited by 130
Chung, E. J., Roh, M., Kwon, O. W., & Koh, H. J. (2008) · Retina · doi:10.1097/iae.0b013e3181754209 · Cited by 114
Davis, M. D., Sheetz, M. J., Aiello, L. P., Milton, R. C., Danis, R. P., Zhi, X., Girach, A., Jimenez, M. C., & Vignati, L. (2009) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-2473 · Cited by 87
Effect of anti-VEGF antibody on retinal ganglion cells in rats
Iriyama, A., Chen, Y.-N., Tamaki, Y., & Yanagi, Y. (2007) · British Journal of Ophthalmology · doi:10.1136/bjo.2007.117309 · Cited by 67
Diabetic retinopathy: a growing concern in an aging population.
Paulus, Y. M., & Gariano, R. F. (2009) · PubMed · Cited by 64
Update on treatments for diabetic macular edema
Fraser‐Bell, S., Kaines, A., & Hykin, P. (2008) · Current Opinion in Ophthalmology · doi:10.1097/icu.0b013e3282fb7c45 · Cited by 49
Self-citation
Cited by
Ranibizumab for Diabetic Macular Edema
Nguyen, Q. D., Brown, D. M., Marcus, D. M., Boyer, D. S., Patel, S., Feiner, L., Gibson, A., Sy, J., Rundle, A. C., Hopkins, J. J., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2011.12.039 · Cited by 1,621
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema
The Diabetic Retinopathy Clinical Research Network (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414264 · Cited by 1,607
The progress in understanding and treatment of diabetic retinopathy
Stitt, A. W., Curtis, T. M., Chen, M., Medina, R. J., McKay, G. J., Jenkins, A., Gardiner, T. A., Lyons, T. J., Hammes, H.-P., Simó, R., et al. (2016) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.08.001 · Cited by 1,164
Intravitreal Aflibercept for Diabetic Macular Edema
Korobelnik, J.-F., Do, D. V., Schmidt-Erfurth, U., Boyer, D. S., Holz, F. G., Heier, J. S., Midena, E., Kaiser, P. K., Terasaki, H., Marcus, D. M., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.05.006 · Cited by 816
Intravitreal Aflibercept for Diabetic Macular Edema
Brown, D. M., Schmidt-Erfurth, U., Do, D. V., Holz, F. G., Boyer, D. S., Midena, E., Heier, J. S., Terasaki, H., Kaiser, P. K., Marcus, D. M., et al. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.06.017 · Cited by 623
Metadata
- Authors
- Michaelides, M., Kaines, A., Hamilton, R. D., Fraser-Bell, S., Rajendram, R., Quhill, F., Boos, C. J., Xing, W., Egan, C., Peto, T., Bunce, C., Leslie, R. D., & Hykin, P. G.
- Venue
- Ophthalmology
- Publisher
- Elsevier BV
- Published
- 2010-06
- Volume
- 117
- Issue
- 6
- Pages
- 1078-1086.e2
- ISSN
- 0161-6420 (ISSN-L)
- OpenAlex
- W2036712095
- Cited by
- 521
- References
- 27
- FWCI
- 47.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.